Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
poly I-poly C12U · 1 trial · 2 indications
To evaluate the potential effectiveness of Ampligen to increase the HAART-free time interval before HIV rebound during the STI of HAART.
| Arm | Type | Description |
|---|---|---|
| Ampligen | EXPERIMENTAL | Ampligen (poly I-poly C12U) 200-400 mg IV infusions given twice weekly for 64 weeks. |
| No Ampligen | NO_INTERVENTION | No Ampligen administered for first 64 weeks |
| Name | Type | Description |
|---|---|---|
| poly I-poly C12U | DRUG | 200-400 mg IV infusions 2x/week for 64 weeks |
1. Adults at least 18 years of age. 2. CD4 cell count of \> 400 cells. 3. Plasma HIV-1 RNA \< 50 copies/ml on two occasions: one within the six weeks prior to starting Baseline and the other during Baseline. 4. History of virologic success with suppression of HIV RNA level \< 50 copies/ml during the...
Poly I-poly C12U, also known as Ampligen, is an investigational small molecule being studied for the treatment of HIV seropositivity and HIV infection. It is being developed by AIM ImmunoTech Inc. (AIM) and is currently in Phase 2 clinical development.
Poly I-poly C12U is a double-stranded RNA molecule that acts as a Toll-like receptor 3 (TLR3) agonist. It is designed to modulate the immune system by stimulating innate immune responses, which may help in the treatment of HIV infection.
Poly I-poly C12U is being developed by AIM ImmunoTech Inc., a biopharmaceutical company listed on the NYSE American under the ticker symbol AIM. The company is conducting clinical trials to evaluate the drug's safety and efficacy in HIV-infected patients.
Poly I-poly C12U is currently in Phase 2 clinical development for the treatment of HIV seropositivity. It is an investigational drug and has not been approved by the FDA. One Phase 2 clinical trial has been completed, with no active trials currently ongoing.
Poly I-poly C12U has been studied in one completed Phase 2 clinical trial, NCT00035893, titled 'The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART.' This trial enrolled 40 participants with HIV seropositivity and HIV infection in the United States.
Yes, poly I-poly C12U is also known as Ampligen. The drug is being developed by AIM ImmunoTech Inc. under the brand name Ampligen for the treatment of HIV infection and other conditions.